Medicine’s John J. Letterio says new cancer vaccine could open chapter in precision immunotherapy

Cancer Vaccine Piggybacks on COVID-19 Mass Immunity

Inside Precision Medicine: John J. Letterio, professor of pediatrics and co-leader of the Developmental Therapeutics Program at Case Comprehensive Cancer—a National Cancer Institute-designated cancer center, commented on the preclinical results that show promise for a cancer vaccine that pairs tumor antigens with viral antigens the immune system has already been trained to recognize. “These findings have provided the scientific rationale to advance this platform into first-in-human studies for patients with sarcoma, a disease where innovative immunotherapeutic approaches are urgently needed. For us, it is only the beginning of what we hope will become a new chapter in precision cancer immunotherapy,” said Letterio.